Peyton Greenside ^Leaders

Peyton Greenside is the Founder and CSO at BigHat Biosciences, a company on a mission to improve human health by making it easier to design advanced, next-generation antibody therapeutics. BigHat Biosciences utilizes an AI-enabled experimental platform that integrates a high-speed characterization "wet" lab with machine learning technologies to speed up the antibody engineering process. The company's focus is on developing safer and more effective treatments for patients suffering from challenging diseases. Backed by several prominent investors, including Section 32, Andreessen Horowitz, Amgen Ventures, and Bristol Myers Squibb, BigHat Biosciences is at the forefront of AI-assisted drug development.